Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
CRCRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP)

NASDAQ Global Market · Currency in USD
$49.66 ▲ +0.27 (+0.54%)
As of Oct 26, 12:34 PM ET. Market open.

Summary

Previous Close
$49.39
Open
$49.35
Day's Range
$49.01 – $50.11
52 Week Range
$44.12 – $67.73
Volume
363,353
Avg. Volume
1,625,141
Market Cap
$4.80B
Beta (5Y Monthly)
1.76
PE Ratio (TTM)
--
EPS (TTM)
-$4.67
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$63.17

Profile: CRISPR Therapeutics AG

Sector
Healthcare
Industry
Biotechnology
Full-time employees
393
CEO
Samarth Kulkarni

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$1.04 · Revenue est. $14.75M
DateEst.Actual
Aug 3, 2026-$1.19-$0.94Beat
May 4, 2026-$1.19-$1.28Miss
Feb 12, 2026-$1.15-$1.37Miss
Nov 10, 2025-$1.26-$1.17Beat
Aug 5, 2025-$1.47-$2.40Miss
May 6, 2025-$1.27-$1.58Miss

Analyst view

Consensus price target
$63.17 ▲ +27.2%
Range $52.00 – $80.00
Rating: Buy
Buy 58% · Hold 37% · Sell 5%

Get free alerts on CRSP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.